Castration-resistant prostate cancers (CRPC) that arise after the failure of androgen-
blocking therapies cause most of the deaths from prostate cancer, intensifying the need to …

Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs
(lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We …

Current prostate cancer (PCa) biomarkers such as PSA are not optimal in distinguishing
cancer from benign prostate diseases and predicting disease outcome. To discover …

Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the
potential to serve as novel markers of disease and to reveal uncharacterized aspects of …

Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage-
and cancer-specific biomarkers that may be relevant in the clinical management of prostate …

Long noncoding RNAs (lncRNA) have recently been associated with the development and
progression of a variety of human cancers. However, to date, the interplay between known …

Hyperactive androgen receptor (AR) activity remains a key determinant of the onset and
progression of prostate cancer and resistance to current therapies. The mechanisms …

High-throughput sequencing of polyA+ RNA (RNA-Seq) in human cancer shows remarkable
potential to identify both novel markers of disease and uncharacterized aspects of tumor …

Abstract Prostate cancer antigen 3 (PCA3) is a prostate-specific long noncoding RNA
(lncRNA) involved in the control of prostate cancer (PCa) cell survival, through modulating …

Prostate cancer (PCa) is the second leading cause of cancer-related death among men in
the United States. Androgen receptor (AR) signaling is the dominant oncogenic pathway in …